Results 101 to 110 of about 483,323 (270)

The 1994 Stevenson Award Lecture. Follicle-stimulating hormone and luteinizing hormone: a tale of two gonadotropins

, 1995
Although most gonadotropes synthesize both luteinizing hormone and follicle-stimulating hormone, the transcription, content, and secretion rates of the two gonadotropins can be separated.
Neena B. Schwartz
core   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

CDK4/6 Inhibitors in the Management of Hormone Receptor‐Positive (HR+)/Human Epidermal Growth Factor Receptor 2‐Negative (HER2−) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Evidence‐informed recommendations emphasize the integration of CDK4/6 inhibitors with endocrine therapy as a central component in the management of HR+/HER2− advanced breast cancer in Indonesia. Expanding access and facilitating integration within national treatment frameworks are crucial to improve outcomes and reduce disparities in care.
Sonar Soni Panigoro, Samuel J. Haryono, Prihantono Prihantono, Dedy Hermansyah, Sumadi Lukman Anwar, Yohana Azhar, Febriyanto Kurniawan, Putu Anda Tusta Adiputra, Kristanto Yuli Yarso, Asdi Wihandono   +9 more
wiley   +1 more source

Effects of Luteinizing Hormone Releasing Hormone Antagonist On The Bovine Corpus Luteum [PDF]

, 1998
The size and function of the corpus luteum were examined after administration of luteinizing hormone releasing hormone antagonist. Luteinizing hormone releasing hormone antagonist was administered to three animal groups starting: 1) 2 days before the ...
Clopton, Debra T., Quintal, Jorge, Kojima, Freddie, Fike, Karol, Kinder, Jim   +4 more
core  

Targeted cytotoxic analog of luteinizing hormone–releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

, 1999
Objective: The aim of the study was to investigate the effects of the cytotoxic analog of luteinizing hormone–releasing hormone AN-207 on the growth of the OV-1063 human epithelial ovarian cancers, which express luteinizing hormone–releasing hormone ...
Szepeshazi, Karoly, Armatis, Patricia, Lamharzi, Najib, Halmos, Gabor, Miyazaki, Masahiro, Schally, Andrew V, Nagy, Attila   +6 more
core   +1 more source

Causal relationship between hormone levels and lung cancer: a Mendelian randomization study

Frontiers in Endocrinology
BackgroundLung cancer is a highly prevalent neoplastic disease in various regions of the world, but the mechanism of its occurrence, development, and metastasis is not clear.
Zhiying Feng, Jingmin Fu, Kangyu Wang, Jiaxin Yang, Xuelian Jiang, Qiong Wu   +5 more
doaj   +1 more source

Effect of Melatonin on the Luteinizing Hormone Release Induced by Clomiphene and Luteinizing Hormone-Releasing Hormone

Experimental Biology and Medicine, 1976
The effect of melatonin on the LH-release response after the administration of synthetic LH-RH and clomiphene citrate was investigated in adult male rats. The sc administration of melatonin (1 mg/day) for 6 days produced a significant decrease in serum LH levels and in seminal vesicles and ventral prostate weights.
J A, Moguilevsky, P, Scacchi, R, Deis, N O, Siseles   +3 more
openaire   +2 more sources

Semen quality in patients with testicular cancer is associated with age and with greatly elevated levels of beta human chorionic gonadotropin

Andrology, EarlyView.
Abstract Background Poor semen quality is a well‐known feature in patients with testicular germ cell tumours (GCTs) at the time of diagnosis but the underlying biological reasons are incompletely understood. Objectives This study aimed to identify GCT‐specific clinical factors that are involved with poor semen quality in GCT patients.
Klaus‐Peter Dieckmann, Johanna Hochmuth‐Tisch, Andrea Salzbrunn, Cord Matthies, Kathrein von Kopylow, Marta Godlewska, Christian Wülfing, Uwe Pichlmeier, Armin Soave, Christian Guido Ruf   +9 more
wiley   +1 more source

Cryopreservation of Spermatozoa Prior and Post‐Orchiectomy in Patients With Testicular Germ Cell Cancer—Does the Timing Matter?

Andrology, EarlyView.
ABSTRACT Background Testicular germ cell cancer (TGCC) is the most frequent malignancy in young men of reproductive age. According to guidelines, semen cryopreservation should be performed prior to orchiectomy. Lack of time and local facilities as well as mental pressure are challenges in terms of fertility preservation before surgery.
Yuhe Tang, Gerald Pühse, Sabine Kliesch, Jann‐Frederik Cremers, Maria Schubert   +4 more
wiley   +1 more source

Contact Activation Is Alleviated by Testosterone Replacement Therapy in Klinefelter Syndrome: Evidence of Hormonal and Metabolic Modulation

Andrology, EarlyView.
ABSTRACT Background Klinefelter syndrome is associated with a markedly increased risk of venous thrombosis. While hypogonadism and metabolic dysfunction are known contributors, the role of the contact activation system in Klinefelter syndrome remains unexplored.
Simon Chang, Claus H. Gravholt, Anne Skakkebæk, Anna‐Marie Bloch Münster, Yaseelan Palarasah   +4 more
wiley   +1 more source